PDF
(Download)
|
- Saffron (Crocus sativus)
- Macular Degeneration
- Retinal Function
| Date:
11-15-2010 | HC# 101061-412
|
Re: Saffron Supplementation Improves Visual Acuity Symptoms of Early Age-related Macular Degeneration
Falsini B, Piccardi M, Minnella A, et al. Saffron
supplementation improves retinal flicker sensitivity in early age-related
macular degeneration. Invest Ophthalmol
Vis Sci. Aug 4, 2010; [Epub ahead of print].
Age-related macular degeneration (AMD) causes the loss of sharp,
central vision. The early stages are characterized by the presence of soft
yellow deposits under the retina known as drusen and hyper- or hypopigmentation
of the retinal pigment epithelium (RPE). Dietary carotenoids have shown
protective effects against AMD, as well as antioxidant effects. The Age-Related
Eye Disease Study Research Group has found that supplementation with
antioxidants may prevent the development of advanced AMD.1 Crocin
and crocetin from saffron (Crocus sativus)
are carotenoid derivatives with antioxidant and anti-apoptotic effects. A study
in rats has shown that saffron has neuroprotective effects against
light-induced photoreceptor degeneration.2 This double-blind,
placebo-controlled clinical trial examined the effect of saffron on the retinal
function of patients with the early stages of AMD.
The researchers enrolled 25 outpatients aged 54-85 years at
the Università Cattolica del Sacro
Cuore in Rome, Italy (12 men and 13 women)
diagnosed with bilateral early AMD. Direct and indirect ophthalmoscopy, retinal
biomicroscopy, and the presence of primary lesions in the macular area were
used to confirm the diagnosis of early AMD. All of the patients had a best
corrected visual acuity of 0.3 or better in the study eye, central fixation,
normal color vision, and no signs of other retinal or optic nerve diseases.
None of the patients were taking medications that affect macular function or
prevent carotenoid absorption. A single grader evaluated the photographs of the
study eyes following a system based on the classification and grading system
for age-related maculopathy and macular degeneration developed by the
International ARM Epidemiological Study Group. The researchers performed
fluorescein angiopathy in order to confirm the presence of early AMD lesions. The
patients were given clinical examinations at baseline and after each 90-day
treatment phase, including a visual acuity test with a Snellen chart, fundus
examination with direct and indirect ophthalmoscopy, and focal
electroretinogram (FERG) testing.
For each patient, the eye with better visual acuity was
designated as the study eye. All study eyes had intermediate AMD with 1 or more
drusen of at least 63 µm in size (mean: 9 drusen, range: 4-22 drusen) and/or
focal macular hypo- or hyperpigmentation. Out of 25 patients, 6 had focal RPE
abnormalities. The patients received either 20 mg/day saffron (n=11) or a
placebo (n=4) for 90 days. [Note: No other information is given regarding the
saffron supplement, i.e., how it was prepared, if it was standardized, or the
identity of the manufacturer.] Following a 15-day wash-out period, patients
were crossed over to the opposite treatment for 90 more days. The main outcome
measures were FERG amplitude, phase, function slope, and threshold, and the
secondary outcome measure was visual acuity.
The authors report "satisfactory" compliance and
the absence of adverse events. Following treatment with saffron, mean FERG log
amplitudes increased compared to baseline levels for all modulation depths
(P<0.001), but the effect was most pronounced at intermediate modulation
depths (P<0.01). These changes were not found after treatment with the
placebo. The mean amplitude increase caused "decrease in both threshold
and slope of the FERG versus modulation depth function." The FERG
modulation threshold decreased an average of 0.26 log units following treatment
with saffron, and it decreased by 0.003 log units after administration of the
placebo (P<0.001). FERG slope decreased from baseline levels by an average
of 1.6 log units following treatment with saffron and by 0.8 log units
following the placebo (P<0.05). There were no clear changes in mean FERG
phase after either treatment. Average Snellen visual acuity increased from 0.7
to 0.8 after saffron treatment, and increased to 0.72 after the placebo
(P<0.01). Treatment with saffron resulted in visual acuity improvements in
20 of 25 patients, while the placebo caused no changes. The researchers did not
find significant changes in ophthalmoscopic appearance following either treatment.
In one representative patient, the authors observed FERG amplitude increases
following the saffron, but not the placebo phase. These changes caused a
reduced FERG threshold.
The authors conclude that treatment with 20 mg/day saffron
for 90 days is "associated with statistically significant changes in the
macular FERG parameters (amplitude and modulation threshold) in early AMD
patients" and an improvement in retinal flicker sensitivity. The mechanism
of action and active constituent(s) are not known, but temporary beneficial
effects on dysfunctional FERG generators, photoreceptors, and bipolar neurons
are proposed by the authors. The authors also conclude that the evidence in
this study does not show neuroprotective effects in early AMD patients but does
show a small statistically significant effect on visual acuity. Further
clinical trials are needed to confirm these results and the mechanism of action.
Supplementation information should be included in all future trials.
—Marissa Oppel-Sutter, MS
References
1.
Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled,
clinical trial of high dose supplementation with vitamins C and E, beta
carotene, and zinc for age-related macular degeneration and vision loss: AREDS
report no. 8. Arch Ophthalmol. Oct
2001;119(10):1417-1436.
2. Maccarone
R, Di Marco S, Bisti S. Saffron supplement maintains morphology and function
after exposure to damaging light in mammalian retina. Invest Ophthalmol Vis Sci. Mar 2008;49(3):1254-1261.
|